Considering these observations, initial triple combination treatment of ALK+ NSCLC cells with ALK‐TKIs plus bypass inhibitors plus GPX4 inhibitors would effectively inhibit the emergence of DTP cells via several different modes of action involving suppression of proliferative signal transduction as well as induction of oxidative damage through upregulation of ROS. The gene discussed is GPX4; the disease is non-small cell lung carcinoma.